PT  - JOURNAL ARTICLE
AU  - Alfadda, Assim A.
AU  - Alzoghaibi, Mohammed A.
TI  - Circulatory neutrophil chemokines in statin-treated diabetic patients
DP  - 2008 Apr 01
TA  - Saudi Medical Journal
PG  - 584--588
VI  - 29
IP  - 4
4099  - http://smj.org.sa/content/29/4/584.short
4100  - http://smj.org.sa/content/29/4/584.full
SO  - Saudi Med J2008 Apr 01; 29
AB  - OBJECTIVE: To assess the effect of statins on the circulatory levels of neutrophil chemokines, namely, granulocyte chemotactic protein-2 GCP-2, growth regulated oncogene-alpha GRO-a and epithelial-cell-derived neutrophil-activating peptide-78 ENA-78 in patients with diabetes.METHODS: We studied 91 diabetic patients 46 were statin-treated and 45 were not and 28 healthy subjects. We measured the levels of GCP-2, GRO-a, and ENA-78 in the serum for the 3 groups using an enzyme linked immunosorbent assay. This cross-sectional study was conducted at King Khalid University Hospital KKUH, Riyadh, Kingdom of Saudi Arabia, from January 2006 to July 2007.RESULTS: Circulating levels of GCP-2, ENA-78, and not GRO-a, were significantly higher in diabetic patients as compared to healthy subjects p<0.05. Statins dropped the levels of both GCP-2 and GRO-a. The ENA-78 levels were not affected by statin therapy. There was no correlation between the levels of these chemokines with the body mass index and glycemia in the population studied.CONCLUSION: Diabetes is associated with an elevation of GCP-2 and ENA-78, and not GRO-a. Statins have a significant role in reducing the level of GCP-2.